A multicenter, randomized, open-label phase 3 study of two anti-angiogenic strategies in advanced hepatocellular carcinoma patients with cross-over at first-line failure: metronomic Capecitabine/Sorafenib (Arm A) vs Sorafenib/metronomic Capecitabine (Arm B).
Latest Information Update: 11 Mar 2024
At a glance
- Drugs Capecitabine (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms Ca.So.
- 08 Mar 2024 Status changed from recruiting to discontinued.
- 05 Aug 2021 New trial record